卡铂联合培美曲塞一线治疗老年肺腺癌患者的疗效及安全性分析

Efficacy and Safety of Carboplatin Combined with Pemetrexed in the First-line Treatment of Elderly Patients with Lung Adenocarcinoma

目的探讨卡铂联合培美曲塞一线治疗老年肺腺癌(LUAD)患者的疗效及安全性。方法选取72例老年LUAD患者,根据化疗方案不同将其分为A组(n=36)和B组(n=36),A组给予顺铂联合培美曲塞治疗,B组给予卡铂联合培美曲塞治疗。比较两组临床疗效、无进展生存期(PFS)及总生存期(OS),观察两组不良反应发生情况,并比较两组生存质量。结果两组客观缓解率(ORR)、疾病控制率(DCR)、PFS及不良反应比较,均无显著差异(P>0.05);B组OS高于A组(P<0.05);B组治疗后生活质量综合评定问卷(QOL)各项评分均高于A组(P<0.05)。结论卡铂联合培美曲塞一线治疗老年LUAD患者疗效良好,能延长患者生存期,安全性较佳,提高患者生活质量。

Objective To investigate the efficacy and safety of carboplatin combined with pemetrexed in the first-line treatment of elderly patients with lung adenocarcinoma(LUAD).Methods A total of 72 elderly patients with LUAD were selected and divided into the group A(n=36)and the group B(n=36)according to the random number table method.The group A was given cisplatin combined with pemetrexed,and the group B was given carboplatin combined with pemetrexed.The clinical efficacy,progression-free survival(PFS)and overall survival(OS)were compared between the two groups,the occurrence of adverse reactions in the two groups was observed,and the quality of life was compared between the 2 groups.Results There was no significant difference in the objective remission rate(ORR),disease control rate(DCR),PFS and adverse reactions between the 2 groups(P>0.05).The OS of group B was higher than that of group A(P<0.05).Scores of items in the quality of life inventory(QOL)in group B after treatment were higher than those in group A(P<0.05).Conclusion Carboplatin combined with pemetrexed in the first-line treatment of elderly patients with LUAD has good curative effect,can prolong the survival period of patients,has good safety and improve the quality of life of patients.